Lobular carcinoma in situ of left breast digital illustration

Lobular carcinoma in situ of left breast Save


ICD-10 code: D05.02

Disease category: D05.0: Lobular carcinoma in situ of breast

Lobular Carcinoma in Situ of Left Breast: A Comprehensive Overview

Lobular carcinoma in situ (LCIS) is a non-invasive condition that affects the lobules, or milk-producing glands, of the breast. Specifically, when LCIS occurs in the left breast, it can raise concerns and require further evaluation and management.

While LCIS is considered a type of breast cancer, it is important to note that it does not typically invade surrounding breast tissues or spread to other parts of the body. Instead, LCIS is often an incidental finding during routine breast screenings or biopsies.

Here are some key points to understand about lobular carcinoma in situ of the left breast:

  1. Prevalence: LCIS is relatively uncommon compared to other types of breast cancer. It is estimated that LCIS accounts for approximately 1-3% of all diagnosed breast cancer cases.
  2. Risk Factors: LCIS is typically found in women between the ages of 40 and 50, and it is more common in women who have not yet reached menopause. Other risk factors may include a family history of breast cancer, early onset of menstruation, late menopause, or hormone replacement therapy.
  3. Diagnosis: LCIS is often detected through a mammogram or breast biopsy. During a biopsy, a small tissue sample is taken from the affected area and examined under a microscope to confirm the presence of LCIS.
  4. Implications: While LCIS itself does not require immediate treatment, it is considered a marker for an increased risk of developing invasive breast cancer in the future. Regular breast screenings, such as mammograms and clinical breast exams, are crucial in monitoring any changes in breast tissue and detecting potential signs of cancer.
  5. Management: Treatment options for LCIS may involve close monitoring, lifestyle modifications, and risk reduction strategies. Depending on individual circumstances, healthcare providers may recommend hormonal therapy, such as selective estrogen receptor modulators (SERMs), to help reduce the risk of developing invasive breast cancer.

It is essential to consult with a healthcare professional to discuss the best management plan for lobular carcinoma in situ of the left breast. Remember, early detection and regular monitoring play a vital role in maintaining breast health and reducing the risk of developing invasive breast cancer.

Treatment of Lobular carcinoma in situ of left breast:

Treatment Options for Lobular Carcinoma In Situ of the Left Breast

Lobular carcinoma in situ (LCIS) of the left breast is a non-invasive condition that begins in the milk-producing glands of the breast. While it does not typically develop into invasive breast cancer, it is considered a marker for an increased risk of developing breast cancer in the future. Treatment options for LCI...

To see full information about treatment please Sign up or Log in